Roche Licenses Zymeworks DLL3 Trispecific T Cell Engager
Zymeworks and Roche agreed on an exclusive worldwide license for ZW209, a DLL3×CD3×CD28 trispecific T cell engager. The verified economics are $55 million upfront after antitrust clearance, $40 million on Phase 1b initiation, up…
